What is the latest price of lenvatinib in China, and how much does it cost after medical insurance reimburses it?

Lenvatinib, known by its brand name Lenvima, is a targeted drug designed to treat certain cancers. Its core component, lenvatinib mesylate, can precisely inhibit multiple kinase targets, effectively curb the proliferation and angiogenesis of tumor cells, thereby achieving the effect of treating cancer. This drug has been approved to treat various cancers such as thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma, and has attracted much attention from the medical community. Next, this article will elaborate on the domestic selling price and medical insurance reimbursement policy of lenvatinib to help patients more comprehensively understand and rationally utilize this drug.

1. Overview of domestic selling prices

The selling price of lenvatinib in China varies depending on the brand, specifications and purchasing channels. The original drug Lenvima lenvatinib mesylate capsules are usually sold at a higher price, with the price of each box being about three to four thousand yuan. However, as the generic drug market booms, more and more versions of generic drugs are emerging, providing patients with more affordable options. Generic drugs purchased through formal channels sell for as low as several hundred yuan per box, which greatly reduces the financial pressure on patients.

2. Detailed explanation of medical insurance reimbursement policy

Fortunately, lenvatinib has been included in the national medical insurance directory, which means that eligible patients can enjoy the financial burden reduction brought by medical insurance reimbursement. However, please note that medical insurance reimbursement is not unconditional, and patients need to meet certain conditions to enjoy reimbursement benefits. These conditions usually include purchasing drugs at designated medical institutions and applying for reimbursement in accordance with prescribed procedures. Patients who do not meet the conditions need to purchase medicines at their own expense.

Medical insurance reimbursement rates and threshold standards vary by region and type of medical insurance. Generally speaking, employee medical insurance can reimburse a certain percentage of expenses, but not the full amount. The specific reimbursement ratio and threshold must be implemented with reference to local medical insurance policies. In addition, there is an annual maximum payment limit for medical insurance reimbursement, and the patient must bear the excess at his own expense.

In summary, lenvatinib, as an important anti-tumor drug, provides patients with an effective treatment. In the domestic market, although original drugs are more expensive, the rise of generic drugs has provided patients with more choices. At the same time, the implementation of the medical insurance reimbursement policy has further reduced the financial burden on patients. However, when using lenvatinib, patients still need to follow the doctor's guidance and use the medication rationally to ensure the therapeutic effect and their own safety.